<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138045</url>
  </required_header>
  <id_info>
    <org_study_id>TODINELI</org_study_id>
    <nct_id>NCT02138045</nct_id>
  </id_info>
  <brief_title>Treatment of Diabetic Neuropathy With Liraglutide</brief_title>
  <acronym>TODINELI</acronym>
  <official_title>A Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to explore whether liraglutide has a long term effect on&#xD;
      clinical symptoms and biomarkers in patients with diabetic neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RIII withdrawal reflex activity (using standard electromyography)</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evoked brain potentials (using standard electroencephalographic brain imaging).</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability/ alterations in simpatico-vagal balance (24 h Holter monitoring)</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting brain activity (spectral analysis of resting brain activity)</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microstructural brain neurodegeneration (assessed by diffuse tensor imaging)</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variety in day/night blood pressure</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut transit assessed by SmartPill (pH, pressure and transit in stomach, small and large intestine)</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitive sensory testing of pressure algometry in muscle</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capacity of descending pain inhibition induced by a cold pressor test (2C in 120 sec)</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of inflammatory cytokines including IL-beta, TNF-alfa, IL6, MCP-1 and specific markers sCD163, sMR, neopterin and HO-1.</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic risk factors expressed as adipokines (adiponectin, leptin, resistin) and inflammatory cell markers</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self assessed symptomatology (Michigan neuropathy screening tool, Quality of life (SF-36), Pain catastrophizing scale (PCS) and self-assessed gastro-intestinal symptoms (PAGI-SYM))</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OCT</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>HbA1C</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Biochemical lipid profile</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate and blood pressure</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Weight/body mass index</measure>
    <time_frame>After 6 months of treatment with Liraglutide</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo solution will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:&#xD;
First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:&#xD;
First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo treatment</intervention_name>
    <description>Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.</description>
    <arm_group_label>Placebo treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide treatment</intervention_name>
    <description>Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.</description>
    <arm_group_label>Liraglutide treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Abile person of Northern European descent&#xD;
&#xD;
          -  Age between 18 to 65 years&#xD;
&#xD;
          -  A verified diagnosis of DM type 1 for minimum 2 years (HbA1C=7%)&#xD;
&#xD;
          -  Stable DM treatment (Treatment is considered stable when the patient has been treated&#xD;
             with basal-bolus insulin, premixed insulin or continously infused insulin with an&#xD;
             insulin dose considered stable by investigator for at least 3 months prior to&#xD;
             screening.)&#xD;
&#xD;
          -  The participants must be able to read and understand Danish.&#xD;
&#xD;
          -  Peripheral diabetic neuropathy ensured by having abnormal nerve conduction velocity&#xD;
&#xD;
          -  BMI equal to or above 22&#xD;
&#xD;
          -  Personally signed and dated informed consent document indicating that the patient has&#xD;
             been informed of all pertinent aspects of the trial.&#xD;
&#xD;
          -  Patients willing and able to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests and other trial procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus type II&#xD;
&#xD;
          -  Estimated glomerular filtration rate (s-creatinin/eGRF) &lt; 60 ml/min/1.37m2&#xD;
&#xD;
          -  Calcitonin &gt; 25&#xD;
&#xD;
          -  HbA1c level &lt; 7%&#xD;
&#xD;
          -  Patients with any clinically significant laboratory abnormalities, that in the opinion&#xD;
             of the investigator may increase the risk associated with trial participation or may&#xD;
             interfere with the interpretation of the trial results.&#xD;
&#xD;
          -  Patients on GLP-1 receptor agonist treatment (exenatide, liraglutide or others) or&#xD;
             pramlintide or any DPP-4 inhibitor within 3 months prior to screening.&#xD;
&#xD;
          -  Other neurological and/or psychiatric disease&#xD;
&#xD;
          -  Treatment of other endocrinological disease except hypothyreosis&#xD;
&#xD;
          -  Malignant neoplasms requiring chemotherapy, surgery, radiation or palliative care in&#xD;
             the previous 5 years.&#xD;
&#xD;
          -  Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial&#xD;
             medullary thyroid carcinoma.&#xD;
&#xD;
          -  Personal history of non-familial medullary thyroid carcinoma&#xD;
&#xD;
          -  Known abuse or alcohol and/or medicine (Alcohol use in accordance with the&#xD;
             recommendations by the Danish Health and Medicines Authority are allowed).&#xD;
&#xD;
          -  Known allergy to liraglutide.&#xD;
&#xD;
          -  Participation in other clinical trials less than 3 months prior to inclusion&#xD;
&#xD;
          -  Female patients who are pregnant or lactating, or intend to become pregnant and male&#xD;
             patients who intend to father a child during course of the study.&#xD;
&#xD;
          -  In women, a serum pregnancy test will be conducted at baseline based on h-CG in the&#xD;
             blood. The investigator will have to ensure that fertile female patients use a safe&#xD;
             contraception method during the study and for at least 15 hours after termination of&#xD;
             the study medication period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asbjørn M. Drewes, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mech-Sense, Department of Medical Gastroenterology, Aalborg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <state>Jutland</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Asbjørn Mohr Drewes</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Diabetic Neuropathy</keyword>
  <keyword>Liraglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

